EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts
Three gene therapy programs for neovascular age-related macular degeneration (nAMD) are nearing phase 3 readouts. AbbVie and REGENXBIO's sura-vec (sura-vec) expects phase 3 results by late 2026. 4D Molecular Therapeutics' 4D-150 (4D-150) phase 3 trials are fully enrolled, with results expected in 2027. Adverum Biotechnologies' ixoberogene soroparvovec (ixo-vec) is in phase 3, with one trial fully enrolled.
How this was made
The 30-second read
Why it matters
While no new data are released, the scheduled readouts constitute a near‑term catalyst for the involved biotech firms.
Market read
Upcoming phase 3 data are a material catalyst for the three biotech firms, potentially influencing the ophthalmology and broader gene‑therapy sectors.
What to watch
Regulatory timelines, manufacturing scale‑up challenges, and reimbursement pathways could delay commercial impact.
Background
The article outlines three gene‑therapy programs targeting neovascular age‑related macular degeneration (nAMD) and their upcoming phase 3 milestones.
Ticker impact
AbbVie is co‑developing the surabgene lomparvovec (sura‑vec) gene therapy with REGENXBIO, with phase 3 readouts expected by end‑2026.
potential upside as market prices in successful phase 3 data
Phase 3 data are a material catalyst; no new data yet, but expectations are set.
REGENXBIO partners with AbbVie on the surabgene lomparvovec (sura‑vec) program, with phase 3 results due by end‑2026.
potential upside if data meet expectations
The company’s value is tied to the upcoming trial outcomes.
Market effects
Advances in neovascular AMD gene therapy could reshape the ophthalmology market and affect competitors.
U.S. biotech sector may see increased investor interest as trial data approach.
Successful therapies could set a precedent for gene‑therapy approaches worldwide.
Counterpoint
If trials miss endpoints, the hype could reverse sharply, penalizing these stocks.
Key entities
- CompanyAbbVie
US‑listed biopharma partner on surabgene lomparvovec.
- CompanyREGENXBIO
US‑listed gene‑therapy developer co‑partnering on surabgene lomparvovec.
- CompanyAdverum Biotechnologies
US‑listed developer of ixoberogene soroparvovec.
